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Abstract
Background: Many women suffer from some degree of intrauterine adhesions (IUAs) 
presenting with various clinical symptoms and signs. Hysteroscopy is the mainstay of diagnosis, 
classification, and treatment of the IUA. Aim: This study was undertaken to review the 
clinical features and treatment outcome in patients diagnosed with Asherman’s syndrome at 
the University of Maiduguri Teaching Hospital (UMTH), Maiduguri, over a 10 years period, 
1997–2006. Subjects and Methods: This is a retrospective study of cases of Asherman’s 
syndrome managed at the UMTH over a 10‑year period, from January 1, 1997 to December 
31, 2006. Case records of the patients were retrieved from medical records’ Department. 
Sociodemographic and clinical information relating to clinical presentations, treatment 
modalities, and outcomes were collated. The data were analyzed using SPSS 16.0 Statistical 
Computer Package (SPSS Inc., IL, USA 2006). Chi‑square and binary logistic regression were 
used for inferential statistics. Results: Asherman’s syndrome constituted 8.1% (81/996) of 
all gynecological operations in UMTH during the study period. The case records retrieval rate 
was 96.3% (78/81 folders). Most of the patients, 59% (46/78) were in their third decade and 
majority 85.9% (67/78) were married. The most common risk factor was pregnancy‑associated, 
accounting for 61.5% (48/78). Infertility and hypomenorrhea were the most common mode of 
presentations in 55.1% (43/78) and 32.1% (25/78) of cases, respectively. Most of the patients 
85.9% (67/78) were treated by blind dilatation and curettage (D/C), Foley’s catheter insertion 
and estrogen‑progesterone combination. Correction of menses was seen in 37.2% (29/78) of 
the patients while the pregnancy rate was 32.1% (25/78). On binary logistic regression age of 
the respondents, multigravidity, and previous pelvic surgeries for pregnancy (C/S and D/C for 
abortion) emerged as the only respondent’s related risk factors associated with the development 
of Asherman’s syndrome. Conclusion: Asherman’s syndrome is relatively common due to 
complications of pregnancy and delivery, and blind D/C has a relatively poor outcome. Age of 
the respondents, multigravidity, and previous pelvic surgeries for pregnancy (C/S and D/C for 
abortion) were associated with the development of Asherman’s syndrome. Therefore, other 
methods of adhesiolysis such as hysteroscopic adhesiolysis should be explored.
Keywords: Asherman’s syndrome, Clinical presentation, Maiduguri, Treatment outcome






This is an open access article distributed under the terms of the Creative 
Commons Attribution‑NonCommercial‑ShareAlike 3.0 License, which allows 
others to remix, tweak, and build upon the work non‑commercially, as long as the 
author is credited and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
How to cite this article: ???
Takai, et al.: Clinical presentation and treatment outcome of Asherman’s syndrome
Annals of Medical and Health Sciences Research | Nov-Dec 2015 | Vol 5 | Issue 6 | 443
Introduction
Intrauterine adhesions (IUA) known as Asherman’s syndrome 
results from trauma to the basal layer of the endometrium.[1-3] It 
most commonly results from curettage of a recently pregnant 
uterus.[4] The lesions range from minor to severe adhesions 
that may affect menstrual function and fertility of the woman. 
Hysteroscopy is the mainstay of diagnosis, classification, and 
treatment of the IUA.[2-5] Severe forms may require multiple 
hysteroscopic adhesiolysis to achieve a satisfactory anatomical 
and functional result.[2-5]
In 1894, Fritsch[1] was the first to report on a case of total 
obliteration of the uterine cavity after a postpartum curettage. 
Thereafter, Asherman published reports in 1948 and 1950 
on 94 additional cases.[2,3] The exact pathophysiologic origin 
of IUA remains unclear. However, pregnancy remains the 
most frequently mentioned event preceding the development 
of Asherman’s syndrome[4-7] and it may follow vaginal 
delivery, cesarean section, and first and second trimester 
abortions.[4,7] Other probable and possible predisposing and 
causative factors of Asherman’s syndrome include abnormal 
decidual development, distorted placentation, placenta previa, 
placenta accrete, defective placental site involution, congenital 
Mullerian tract anomalies, DES exposure,[8] embolization of 
uterine arteries, and endometrial ablation.[2-5]
The majority of the patients with IUAs present with 
menstrual abnormalities, usually hypomenorrhea or 
secondary  amenorrhoea.[9] Others may have relatively normal 
menses and in which case a high index of suspicion is needed 
to make diagnosis.[10] Hysterosalpingography (HSG) remains 
the most common method of diagnosis.[11,12] Most of the cases 
in University of Maiduguri Teaching Hospital (UMTH) were 
diagnosed by HSG. Other methods of diagnosis include 
hysteroscopy, saline infusion sonography, three-dimensional 
ultrasound scanning and magnetic resonance imaging.[13-17] 
Dilatation and curettage (D/C) was widely used before the 
widespread use of hysteroscopy, and reported results in a 
previous study included return to normal menses in 1049 of 
1250 women (84%), conception in 559 of 1049 women (53%), 
miscarriages in 142 of 559 pregnancies (25%), term delivery in 
306 of 559 pregnancies (55%), premature delivery in 50 of 559 
pregnancies (9%), and 42 of 559 pregnancies (8%) complicated 
by placenta accreta.[18]
The use of a Foley catheter for 3–10 days after surgical lysis 
of IUAs is similarly reported to act as a physical intrauterine 
barrier.[19-24] A nonrandomized study compared the use of 
an inflated pediatric Foley catheter in place for 10 days 
postoperatively in 59 patients with that of an intrauterine 
device (IUD) in situ for 3 months in 51 patients.[25] There were 
fewer infections in the Foley group and a lower recurrence 
rate of IUAs as assessed using HSG.[25] Although amenorrhea 
continued in 19% of women in the Foley group and 38% in the 
IUD group, the fertility rate was relatively low in both groups: 
20 of 59 (34%) and 14 of 51 (28%), respectively. In a study of 
25 women with moderate to severe IUAs, use of a fresh amnion 
graft over an inflated Foley catheter prevented recurrence of 
IUAs in 52% of women although follow-up fertility data and 
complications are not reported.[24] Postoperative treatment 
with estrogen therapy (a daily oral dose of 2.5 mg conjugated 
equine estrogen with or without opposing progestin for 2 or 
3 cycles) has been advocated by various authors.[26-28] This 
study was undertaken to assess the prevalence of Asherman’s 
syndrome at the UMTH, mode of presentation and outcome 
of treatment using blind D/C. The findings will be a basis for 
recommendation for the hospital management to acquire better 
machines such as the hysteroscope for diagnosis and treatment 
of Asherman’s syndrome in our center.
Subjects and Methods
This is a retrospective study of cases of Asherman’s syndrome 
seen and treated at the UMTH, Maiduguri, Borno State, Nigeria 
over a 10-year period; from January 1, 1997 to December, 31, 
2006. Ethical approval was obtained from Health Research 
Ethics Committee of UMTH.The theater records for all cases 
of IUA treated over the study period were compiled, and the 
case notes retrieved from the medical records department 
and relevant data for the study was extracted. Diagnosis was 
made using HSG and treatment was by blind D/C, insertion 
of Pediatrics Foley’s catheter and administration of combined 
estrogen/progesterone therapy (conjugated equine estrogen 
0.625 mg daily for 21 days and thereafter norethisterone 
acetate 10 mg daily for 7 days). Lippes loop was used in a 
few patients when available. The procedure was done after 
obtaining consent. Preoperative assessments were also found to 
be satisfactory before the procedure. Under general anesthesia 
and in lithotomy position, routine cleaning and draping were 
done. Sequential uterine dilatation was done using Hegar’s 
dilators up to 8–10 mm. Postoperative conditions were 
satisfactory. Information on age, parity, clinical presentation, 
diagnostic modality, predisposing factors, treatment modality, 
and outcome were extracted. Main outcome measures 
were return to normal menses, conception, miscarriages in 
pregnancies, term delivery and premature delivery. Patients 
were followed-up for 2 years, and those who could not be 
followed-up were excluded from the study. The data were 
analyzed using SPSS 16.0 Statistical Computer Package 
(SPSS Inc., IL, USA, 2006). The Chi-square was used for 
bivariate analysis, and binary logistic regression was used 
to determine risk factors associated with the development 
of Asherman’s syndrome. A P < 0.05 was considered as 
statistically significant. The results were presented by simple 
statistical tables.
Results
There were 996 gynecological operations during the period 
under study, out of which 81 were for Asherman’s syndrome. 
Therefore, 8.1% of gynecological surgeries done were for 
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Asherman’s Syndrome. Seventy-eight of the folders were 
retrieved and analyzed, giving a retrieval rate of 96.3%. The 
sociodemographic factors studied are presented in Table 1. 
The age of the patients ranged between 18 and 42 years, with 
most 46/78 (59%) in their third decade; only 12/78 (15.4%) 
were below 20 years while 6/78 (7.7%) were aged 40 years 
and above. There were 9/78 (11.8%) unmarried women; 
2/78 (2.6%) were divorced while the majority 67/78 (85.9%) 
of the patients were married and up to 62/78 (79.5%) of them 
were having more than one delivery. Almost 3/4 of the patients, 
59/78 (71.8%) had primary school education; 14/78 (17.9%) 
had secondary education, 6/78 (7.7%) had tertiary education, 
while the remaining 2/78 (2.6%) had no formal education.
The risk factors associated with Asherman’s syndrome 
are shown in Table 2. The commonest risk factor was 
pregnancy-associated, accounting for 48/78 (61.5%), of which 
21/78 (26.9%) followed cesarean section, 13/78 (16.7%) were 
due to puerperal infection while 14/78 (17.9%) were due to 
D/C for abortion and its complications. Myomectomy was 
responsible for 14/78 (17.9%) of cases, pelvic inflammatory 
disease for 5/78 (6.4%) and D/C for infertility 8/78 (10.3%); 
while 3/78 (3.9%) was due to unspecified causes.
This study observed that age of the respondents (25–29 years), 
marital status (married), having at least secondary school level of 
education, multigravidity, previous cesarean section, puerperal 
infection, D/C for abortion, and D/C for infertility were 
significantly associated with the development of Asherman’s 
syndrome. On binary logistic regression in a model consisting 
of these variables, age of the respondents, multigravidity, and 
previous pelvic surgeries for pregnancy (C/S and D/C for 
abortion) emerged as the only respondent’s related risk factors 
associated with the development of Asherman’s syndrome in 
this study [Table 3].
Table 4 shows the clinical presentations of Asherman’s 
syndrome. Infertility and hypomenorrhea were the commonest 
mode of presentations in 43/78 (55.1%) and 25/78 (32.1%) of 
cases respectively, amenorrhea and infertility in 7/78 (9.0%) 
and oligomenorrhea 3/78 (3.8%). Adhesiolysis and Foley’s 
catheter insertion with estrogen-progesterone combination 
were the most frequent treatment modality in 67/78 (85.9%) 
of the patients. The remaining 11/78 (14.1%) had Lippes’ 
loop insertion.
Correction of menses was seen in 29/78 (37.2%) of the patients; 
the pregnancy rate was 32.1% (25/78); while 21/78 (26.9%) 
had no change from the treatment. Only in 3.8% (3/78) of 
the patients was there worsening of symptoms. These are 
presented in Table 5.
Discussion
The study evaluated the incidence, clinical presentation and 
treatment modalities and outcome of patients presenting with 
Asherman’s syndrome at the UMTH Maiduguri, North-Eastern 
part of Nigeria. Though the true incidence of IUAs is difficult 
to establish, the condition is rare in the general population 
and often asymptomatic. The 8.1% of gynecological surgeries 
done for Asherman’s Syndrome in our study lies within a 
reported estimated range of 1.5% as an incidental finding 
at HSG to 21.5% of women with a history of postpartum 
uterine curettage.[29,30] The findings on age distribution 
among the patients studied agree well with previous reports 
where the majority of their patients were as well in their third 
decades.[10,28,31] This group of patients may exhibit better health 
seeking behavior than their counterpart in the extreme of ages 
for one reason or the other.
The most common risk factor associated with IUAs in this 
study was pregnancy-associated, accounting for 61.5%. This 



























Table 2: Risk factors associated with Asherman’s syndrome
Risk factor n (%)
Cesarean section 21 (26.9)
Puerperal infection 13 (16.7)
D/C for abortion 14 (17.9)
Myomectomy 14 (17.9)
PID 5 (6.4)
D/C for infertility 8 (10.3)
Unspecified 3 (3.9)
Total 78 (100)
PID: Pelvic inflammatory disease, D/C: Dilatation and curettage
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finding is in keeping with previous studies.[4-7,9,10] The lesions 
range from minor to severe adhesions that may affect menstrual 
function and fertility of the woman.[3-5]
Infertility was the commonest mode of presentation in up to 
55.1% of our patients and 44.9% had associated menstrual 
irregularities. Studies from Lagos reported menstrual irregularity 
in form of hypomenorrhea as most common presentation.[10,12]
Though blind D/C and Foley’s catheter insertion is associated 
with high incidence of uterine perforation and low success 
rate,[17] it was the treatment modality employed in most (85.9%) 
of our patients together with estrogen-progesterone 
combination. The remaining 14.1% had Lippe’s loop insertion. 
We did not encounter any uterine perforation though our 
pregnancy outcome was poor when compared with as high 
as 45% reported in another study.[11] This was probably 
because of unavailability of hysteroscope, as a gold standard 
tool used for the diagnosis and treatment of IUAs,[16] at that 
time in our center. After controlling for confounders, some 
sociodemographic and reproductive characteristics of the 
respondents as shown in Table 3 were significantly associated 
with the development of Asherman’s syndrome. This finding 
agrees with the finding from a study in Danish population.[32]
In consonant with our study, many previous studies reported 
the use of blind D/C and Foley’s catheter insertion together 
with postoperative use of estrogen-progesterone combination 
therapy with good results.[18-24,26-28] Correction of menses 
was seen in 37.2% of our patients while the pregnancy 
rate was 32.1%. The results were comparable to that of 
a previous study that reported that the group treated with 
Foley’s catheter showed conception rate of 34% and a lower 
recurrence rate of IUAs.[25] Other researchers similarly 
reported intrauterine pregnancies rates ranging from 22% to 
45% and live births range from 28% to 32%.[11] Some studies 
reported better results including return to normal menses in 
1049 of 1250 women (84%) and conception in 540 of 1052 
women (51%).[18]
Asherman’s syndrome is relatively common due to 
complications of pregnancy and delivery, and blind D/C has 
a relatively poor outcome. This study is limited in the sense 
that it was retrospective and did not compare outcome of 
treatment with other methods of adhesiolysis. Therefore, other 
methods of adhesiolysis such as hysteroscopic adhesiolysis 
should be explored.
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